Impact of Drug Resistance Mutations in HIV-1 Infected Children
Author Information
Author(s): Amisha Malhotra, Sunanda Gaur, Patricia Whitley-Williams, Caitlin Loomis, Anna Petrova
Primary Institution: University of Medicine and Dentistry of New Jersey (UMDNJ) – Robert Wood Johnson Medical School
Hypothesis
How do protease inhibitor associated mutations affect therapy efficacy in HIV-1 infected pediatric patients?
Conclusion
Primary PR resistance mutations significantly increase the likelihood for high viral replication in pediatric patients with moderate/severe HIV-1 infection.
Supporting Evidence
- Primary mutations in the protease gene increased the likelihood of plasma viral load ≥ 10,000 copies/mL.
- Viremia ≥ 10,000 copies/mL was recorded in almost all children with primary mutations in the PR region.
- Combined ARV regimens did not significantly influence the incidence of NRTI and NNRTI associated mutations.
Takeaway
This study found that certain mutations in the virus can make it harder for children with HIV to respond to treatment, leading to higher levels of the virus in their blood.
Methodology
A cross-sectional study evaluated the impact of treatment regimens and resistance mutation patterns on the clinical, virological, and immunological presentation of HIV disease in 41 children.
Limitations
The study did not analyze the impact of treatment interruptions on virologic and immunologic outcomes.
Participant Demographics
41 children (25 male and 16 female) with moderate/severe HIV-1 infection.
Statistical Information
P-Value
p<0.008
Confidence Interval
1.15, 2.52
Statistical Significance
p<0.008
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website